Leiden, Netherlands
HALIX is constructing a 72,000-sf cGMP facility at Leiden Bio Science Park in the Netherlands. Utilizing 1000-liter, single-use bioreactors, the five-story building will accommodate the development and manufacture of biopharmaceutical drug substances for clinical and commercial applications. Housing labs for process development, analytical development, and quality control, the structure will feature cleanrooms with unidirectional process flows with separate areas for protein manufacturing and the production of viral vaccines and viral vectors. Construction began on the project in July of 2018 with full operations expected to commence in late 2019.